ArticleUrology case reports2026
Transperineal laser ablation for 300-gram benign prostatic hyperplasia in an inoperable high-risk patient: Expanding the therapeutic horizon.
Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transperineal laser ablation (TPLA) is an emerging minimally invasive option for benign prostatic hyperplasia, but its role in massive glands remains undefined. We report a 78-year-old catheter-dependent man with a 300-g prostate, severe cardiopulmonary comorbidity, left ventricular ejection fraction of 25%, and mandatory dual antiplatelet therapy, making standard surgery unsafe. Total-gland TPLA was performed under local anesthesia using eight fibers and 42,300 J without complications. The patient became catheter-free after 15 days, with Qmax improving to 19.3 mL/s and prostate volume decreasing to 90 g at six months. TPLA may be feasible in selected high-risk patients with extreme BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.